Skip to main content

Chancery Court Issues Important Decision Relating to Buyer Indemnification Rights and Seller Participation Rights in Connection with Post-Closing Governmental Investigations—Anthem

M&A/PE Briefing | May 9, 2023

In LPPAS Representative, LLC v. ATH Holding Company, LLC (“Anthem”) (May 2, 2023), the Delaware Court of Chancery held that a buyer of several healthcare-related companies had vitiated its indemnity rights against the sellers by failing to comply with common provisions of the sale agreement giving the sellers a right to participate in the acquired companies’ defense strategy with respect to post-closing governmental investigations relating to the acquired companies’ pre-closing conduct.

Key Points

  • The decision indicates that certain actions that a buyer may take after post-closing discovery of regulatory or criminal violations at the acquired company—even when such actions were legally required or commonly considered good practice—may limit the buyer’s indemnification rights with respect to those violations. Chancellor Kathaleen St. J. McCormick found that the buyer’s decision to respond to Department of Justice (“DOJ”) subpoenas and engage in discussions with the DOJ and another regulatory agency, as well as the buyer’s self-reporting of additional possible violations, without first obtaining input from the sellers, violated the sellers’ participation rights provided for in the indemnification provisions of the sale agreement.
  • The decision may impact buyers’ substantive strategy when dealing with the government in connection with such post-closing discoveries and investigations.  Buyers often want to “get out front” with the DOJ or other regulators to convey the message that, regardless of what may have occurred under prior ownership, the new owners are committed to compliance and to “cleaning up” whatever problem they inherited. Buyers may consider a rapid response, or a demonstrable break and independence from prior ownership, to be strategically important, especially when seeking cooperation credit or leniency from a regulator, or the ability to conduct its own investigation and report the results to the regulator. This decision may limit the buyer’s ability to distance itself from the seller in that way.
  • The decision has broad applicability. While this case related to possible Medicare fraud, the court’s holding is important to buyers of any companies that regularly deal with regulatory authorities (among many possible examples, defense contractors, investment advisors, energy companies, and so on) and that respond to governmental subpoenas and civil investigative demands.

Background. In late 2016, pursuant to a Purchase Agreement, Highland Acquisition Holdings, LLC acquired two groups of Florida-based entities (together, the “Acquired Entities”) from their respective owners (together, the “Sellers”). In 2017, Anthem, Inc. acquired Highland (and so became the owner of the Acquired Entities). The Acquired Entities operated, together, as an integrated health plan, medical center network, and pharmacy; and included a Medicare Advantage Organization (MAO) that maintained networks of medical providers to service clients who were Medicare-eligible enrollees. After the closing, Anthem discovered what it believed to be fraudulent coding practices that the Sellers had engaged in so that the Acquired Entities would receive excessive Medicare Advantage reimbursement from the Centers for Medicare and Medicaid Services (“CMS”).

Anthem reported the information to CMS and the DOJ; later had discussions relating to liability, and executed tolling agreements, with both agencies; and subsequently provided notice to the Sellers that it would be seeking indemnification relating to the DOJ’s and CMS’s investigations. Anthem did not contact the Sellers to provide them with an opportunity to participate in or provide input with respect to the defense strategy for the investigations. The Sellers brought suit against Anthem for violating their rights, under the indemnification provisions of the Purchase Agreement, to participate in the defense of claims arising from governmental or criminal investigations. Chancellor McCormick granted summary judgment in favor of the Sellers, finding that Anthem had breached the Sellers’ participation rights—and correspondingly had abrogated any indemnity obligation—by having “unilaterally steer[ed]” the acquired companies’ defense.

Discussion

The Purchase Agreement’s participation rights provisions. As is typical, the Purchase Agreement provided that, when one party indemnifies the other, the Indemnifying Person has the right to control the defense of third-party litigation. As is also typical, the Purchase Agreement provided that, with respect to claims by a governmental regulator, in lieu of a right to control the defense, the Indemnifying Person would have the right to participate in the defense. The Purchase Agreement expressly set forth that the participation rights of the Sellers (as the Indemnifying Person) in this context included obligations of the buyer to (i) select nationally recognized counsel to lead the defense; (ii) consult regularly (at least once per week) with the Sellers; (iii) give the Sellers a chance to review and comment on correspondence with the governmental authority; (iv) allow the Sellers “to actively participate” in relevant matters, including the chance to attend “proceedings, meetings, negotiations, and conferences”; and (v) enter into a joint defense agreement with the Sellers.

Anthem’s violation of the Sellers’ participation rights. Anthem did not dispute the plaintiffs’ factual allegations relating to its not including Anthem in the defense strategy, but argued that its actions did not constitute a breach of the Sellers’ participation rights because it had substantially complied with the Purchase Agreement. Anthem argued that, as the Sellers did not have the right to control the defense, any failure to permit their participation did not materially disadvantage them (as Anthem could have ignored their input). The court disagreed. Under the Purchase Agreement provisions, the court stated, the Sellers “were entitled to a seat at the table, which they did not receive.” The court also rejected Anthem’s argument that not including the Sellers in the defense was immaterial as the Sellers had been participating in the DOJ’s criminal investigation (including having retained separate criminal counsel and having been communicating directly with the DOJ) and the Sellers had not consulted with Anthem about their defense. The court noted that the Purchase Agreement did not grant the buyer participation rights in the Sellers’ defense—which, the court stated, “perhaps…create[d] lopsided obligations, [but] it is what the parties agreed.”

Practice Points

  • Before engaging with a regulator about a potential or actual investigation into pre-closing alleged issues, a buyer should carefully review its obligations under the sale agreement with respect to participation rights of the seller. Failure to provide the seller with the participation rights set forth in the sale agreement could affect, or even be fatal to, the buyer’s indemnification rights with respect to losses arising from the investigation.
  • Consideration should be given to modifying standard participation right provisions. Among the relevant considerations would be the respective negotiating leverage of the parties and the perceived level of risk that post-closing regulatory investigations might arise. Among the possible modifications would be: First, at a minimum, providing greater clarity and specificity as to the timing and extent of any right of the seller to participate in the defense strategy. For example, the parties may wish to specify more precisely than is typical the triggering event for the seller’s participation right—whether it is any inquiry from a regulator that could lead to an investigation; or the formal commencement of an investigation; or an investigation having proceeded to a specified point; or a specific claim having been formally asserted by the regulator. Second, a buyer may wish expressly to exclude specified actions from the participation rights—such as initial self-reporting of possible violations and responses to subpoenas or other legally required actions. Such modifications may be particularly appropriate in light of the DOJ’s and other regulators’ ongoing efforts to incentivize prompt self-reporting. Third, a buyer may wish to provide for its own participation rights with respect to the seller’s own, separate defense in connection with regulatory or criminal investigations of the seller’s pre-closing conduct.

This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.